ArticleResearch and practice in thrombosis and haemostasis2026
Prophylactic anticoagulation in isolated tumor thrombus: a single-center retrospective cohort study.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal management of isolated tumor thrombus (TT) remains unknown. Although therapeutic anticoagulation is indicated for concurrent bland thrombosis or history of venous thromboembolism, current guidelines do not specifically address isolated TT, and recent studies have not shown consistent benefit of anticoagulation in this setting. Objectives: This study described the characteristics of patients with isolated TT managed at Gustave Roussy Comprehensive Cancer Center for over 5 years and explored outcomes, including overall survival, thrombotic events, and bleeding, across different anticoagulation strategies. Methods: This retrospective single-center cohort study included consecutive adults with imaging-confirmed isolated TT managed at Gustave Roussy from November, 2018 to June, 2024. Patients receiving therapeutic anticoagulation for any indication were excluded. The primary outcome was overall survival. Secondary outcomes were incident thromboembolic events and bleeding. Results: Among 1262 screened records, 29 patients with isolated TT met eligibility criteria (mean age 55.6 ± 15.7 years; 75.9% male; 93.1% had stage IV cancer). Ten received prophylactic-dose anticoagulation, and 19 received no anticoagulation. Restricted mean overall survival was 50.7 months (95% CI, 43.3-58.06) in the prophylactic anticoagulation group vs 20.8 months (95% CI, 10.8-30.9) in the no-anticoagulation group. New bland thrombosis and bleeding events were infrequent and did not differ significantly between groups. Conclusion: In this small retrospective cohort, longer survival was observed in patients receiving prophylactic-dose anticoagulation. This finding may reflect residual confounding and selection of patients with more favorable prognosis rather than a true therapeutic effect and should therefore be interpreted with considerable caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.